Oncobiologics Inc (ONS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oncobiologics Inc (ONS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8222
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncobiologics Inc (Oncobiologics) is a clinical stage biopharmaceutical company that identifies, develops, manufactures and commercializes biosimilar therapeutics in the areas of immunology and oncology. The company’s pipeline products include ONS-3010, an adalimumab biosimilar intended for rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease and ulcerative colitis; and ONS-1045, a bevacizumab (Avastin) biosimilar intended to treat non-squamous non-small cell lung cancer. The company also develops various preclinical biosimilar product candidates including ONS-1050, a trastuzumab biosimilar that interferes with human epidermal growth factor receptor 2; ONS-4010, a biosimilar to denosumab; and ONS-3040, a biosimilar to ustekinumab. It develops products through strategic collaborations and partnerships with biotechnology and pharmaceutical companies. Oncobiologics is headquartered in Cranbury, New Jersey, the US.

Oncobiologics Inc (ONS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Oncobiologics Raises Additional USD13 Million in Venture Financing 12
Oncobiologics Raises USD31 Million in Financing Round 13
Partnerships 14
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14
Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18
Licensing Agreements 19
Oncobiologics Enters into Licensing Agreement with GMS Tenshi 19
Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 20
Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21
Ipca Labs Amends Licensing Agreement with Oncobiologics 22
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 23
Equity Offering 24
Oncobiologics Raises USD7.5 Million in Second Tranche of Private Placement of Shares and Warrants 24
Oncobiologics Raises USD7.5 Million in First Tranche of Private Placement of Shares and Warrants 25
Oncobiologics Plans to Raise Funds through Public Offering of Shares 26
Oncobiologics Raises USD25 Million in Private Placement of Preferred Shares and Warrants 27
Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 30
Oncobiologics Raises USD35 Million in IPO of Units 31
Oncobiologics to Raise USD5 Million in Private Placement of Units 33
Oncobiologics Raises USD4 Million in Private Placement of Shares 34
Oncobiologics Raises USD7 Million in Private Placement of Shares 35
Debt Offering 36
Oncobiologics Raises USD1.5 Million in Third and Final Tranche of Private Placement of Notes and Warrants Due 2017 36
Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 37
Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 38
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 39
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 40
Oncobiologics Inc – Key Competitors 41
Oncobiologics Inc – Key Employees 42
Oncobiologics Inc – Locations And Subsidiaries 43
Head Office 43
Recent Developments 44
Financial Announcements 44
Aug 14, 2018: Oncobiologics povides business update and reports third quarter financial results for fiscal 2018 44
May 15, 2018: Oncobiologics Announces Second Quarter Financial Results for Fiscal 2018 45
Feb 14, 2018: Oncobiologics Reports Q1 Fiscal 2018 Financial Results 46
Corporate Communications 49
Aug 02, 2018: Oncobiologics appoints Lawrence A. Kenyon as president and CEO 49
Jul 11, 2018: Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements 50
Apr 17, 2018: Oncobiologics Appoints Randy Thurman To Board Of Directors 51
Mar 27, 2018: Oncobiologics Names Dr. Joerg Windisch As Board Director 52
Feb 13, 2018: Oncobiologics Receives Positive Nasdaq Listing Determination 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Oncobiologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oncobiologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oncobiologics Raises Additional USD13 Million in Venture Financing 12
Oncobiologics Raises USD31 Million in Financing Round 13
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14
Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18
Oncobiologics Enters into Licensing Agreement with GMS Tenshi 19
Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 20
Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21
Ipca Labs Amends Licensing Agreement with Oncobiologics 22
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 23
Oncobiologics Raises USD7.5 Million in Second Tranche of Private Placement of Shares and Warrants 24
Oncobiologics Raises USD7.5 Million in First Tranche of Private Placement of Shares and Warrants 25
Oncobiologics Plans to Raise Funds through Public Offering of Shares 26
Oncobiologics Raises USD25 Million in Private Placement of Preferred Shares and Warrants 27
Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 30
Oncobiologics Raises USD35 Million in IPO of Units 31
Oncobiologics to Raise USD5 Million in Private Placement of Units 33
Oncobiologics Raises USD4 Million in Private Placement of Shares 34
Oncobiologics Raises USD7 Million in Private Placement of Shares 35
Oncobiologics Raises USD1.5 Million in Third and Final Tranche of Private Placement of Notes and Warrants Due 2017 36
Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 37
Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 38
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 39
Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 40
Oncobiologics Inc, Key Competitors 41
Oncobiologics Inc, Key Employees 42

List of Figures
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Oncobiologics Inc (ONS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Informa PLC (INF):企業の財務・戦略的SWOT分析
    Informa PLC (INF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Oxford Gene Technology Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Oxford Gene Technology Ltd (OGT) is a provider of genetics research solutions. The company’s products comprise fish probes, custom cancer panels, custom AML panel, custom breast cancer panel, custom FH panel, core MPN panel, ovarian cancer panel, myeloid panel and others. It provides medical …
  • 3M Co (MMM)-エネルギー分野:企業M&A・提携分析
    Summary 3M Company (3M) is a diversified technology company that specializes in the development, manufacture and marketing of a wide range of innovative products. The company develops technology platforms, including adhesives, abrasives, light management, microreplication, non woven materials, nanot …
  • WIV Wein International AG:企業の戦略・SWOT・財務分析
    WIV Wein International AG - Strategy, SWOT and Corporate Finance Report Summary WIV Wein International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Vivendi SA (VIV):企業の財務・戦略的SWOT分析
    Vivendi SA (VIV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • McKinsey & Co Inc:企業の戦略的SWOT分析
    McKinsey & Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • WSI Industries, Inc.:企業の戦略・SWOT・財務情報
    WSI Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary WSI Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Bank of Montreal:戦略・SWOT・企業財務分析
    Bank of Montreal - Strategy, SWOT and Corporate Finance Report Summary Bank of Montreal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Wns (Holdings) Limited
    Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Wns (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Wirtgen GmbH:企業の戦略・SWOT・財務情報
    Wirtgen GmbH - Strategy, SWOT and Corporate Finance Report Summary Wirtgen GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • PTC, Inc. (PTC):企業の財務・戦略的SWOT分析
    PTC, Inc. (PTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Dermala Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Dermala Inc (Dermala) is a healthcare products manufacturer that offers skin care products. The company offers acne treatment products such as zinc, acne spot treatment, acne pimple patches, advanced probiotics, acne treatment pads, and acne treatment system. It uses the human microbiome and …
  • Williams Partners LP:企業のM&A・事業提携・投資動向
    Williams Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Williams Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Time Inc.:企業のM&A・事業提携・投資動向
    Time Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Time Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Phillips 66 Co (PSX):企業の財務・戦略的SWOT分析
    Phillips 66 Co (PSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Coca-Cola Amatil Limited:戦略・SWOT・企業財務分析
    Coca-Cola Amatil Limited - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola Amatil Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Triskalia SCA:企業の戦略・SWOT・財務情報
    Triskalia SCA - Strategy, SWOT and Corporate Finance Report Summary Triskalia SCA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • China Petrochemical Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary China Petrochemical Corp (Sinopec Corp) is a petroleum and petrochemical company. The company is engaged in the engaged in the exploration and production, pipeline transportation, and sale of petroleum and natural gas. It is also involved in the production, sale, storage and transportation o …
  • Meridian Bioscience Inc (VIVO):医療機器:M&Aディール及び事業提携情報
    Summary Meridian Bioscience Inc (Meridian) is a fully integrated life science company that carries out the development, manufacturing and distribution of diagnostic test kits for viral, gastrointestinal, respiratory and parasitic infectious disease indications. It also manufactures bulk antigens, an …
  • Novo Nordisk AS (NOVO B):企業の財務・戦略的SWOT分析
    Novo Nordisk AS (NOVO B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆